Analystreport

Cocrystal Pharma (NYSE: COCP) had its "buy" rating re-affirmed by analysts at HC Wainwright.

Cocrystal Pharma, Inc.  (COCP) 
NASDAQ:AMEX Investor Relations: cocrystalpharma.com